Haemonetics (NYSE:HAE) vs. Guided Therapeutics (OTCMKTS:GTHP) Head to Head Review

Haemonetics (NYSE:HAE) and Guided Therapeutics (OTCMKTS:GTHP) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, institutional ownership, dividends, risk, earnings, analyst recommendations and profitability.

Risk and Volatility

Haemonetics has a beta of 0.36, meaning that its stock price is 64% less volatile than the S&P 500. Comparatively, Guided Therapeutics has a beta of 0.75, meaning that its stock price is 25% less volatile than the S&P 500.

Insider and Institutional Ownership

99.7% of Haemonetics shares are held by institutional investors. Comparatively, 9.7% of Guided Therapeutics shares are held by institutional investors. 1.8% of Haemonetics shares are held by company insiders. Comparatively, 66.8% of Guided Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Haemonetics and Guided Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Haemonetics	13.31%	27.32%	9.61%
Guided Therapeutics	N/A	N/A	-246.42%

Analyst Ratings

This is a summary of recent ratings for Haemonetics and Guided Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Haemonetics	0	4	6	1	2.73
Guided Therapeutics	0	0	0	0	0.00

Haemonetics currently has a consensus target price of $83.89, indicating a potential upside of 47.72%. Given Haemonetics’ stronger consensus rating and higher probable upside, analysts clearly believe Haemonetics is more favorable than Guided Therapeutics.

Valuation & Earnings

This table compares Haemonetics and Guided Therapeutics”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Haemonetics	$1.36 billion	1.94	$167.68 million	$3.63	15.64
Guided Therapeutics	$770,000.00	28.83	-$2.42 million	($0.04)	-6.00

Haemonetics has higher revenue and earnings than Guided Therapeutics. Guided Therapeutics is trading at a lower price-to-earnings ratio than Haemonetics, indicating that it is currently the more affordable of the two stocks.

Summary

Haemonetics beats Guided Therapeutics on 12 of the 15 factors compared between the two stocks.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, it provides Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and VASCADE products comprising VASCADE and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen. The company sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.

About Guided Therapeutics

Guided Therapeutics, Inc., a medical technology company, focuses on developing medical devices. It focuses on the commercialization of LuViva, a non-invasive cervical cancer detection device that identifies cervical cancers and precancers painlessly, non-invasively, and at the point-of-care by scanning the cervix with light, then analyzing the light reflected and fluorescent light. The company was formerly known as SpectRx, Inc. and changed its name to Guided Therapeutics, Inc. in February 2008. Guided Therapeutics, Inc. was incorporated in 1992 and is based in Norcross, Georgia.